Loading organizations...
§ Private Profile · Cincinnati, OH, USA
Clinical-stage biotechnology company developing multi-target therapeutics for dermatological diseases, including atopic dermatitis.
Alphyn Biologics is a clinical-stage biotechnology company developing multi-target therapeutic drug candidates for severe dermatological conditions, operating from dual headquarters in Annapolis, Maryland, and Cincinnati, Ohio. The enterprise utilizes a proprietary plant-based platform featuring multiple bioactive compounds to create topical treatments that simultaneously address itch, inflammation, and bacterial infections. Its lead pharmaceutical candidate, Zabalafin (AB-101), recently completed Phase 2 clinical trials for atopic dermatitis, while a secondary asset targets the molluscum contagiosum virus. The pre-revenue firm finances its research through venture capital, accumulating over $31 million in total backing after closing a $6.7 million Series A and a subsequent $25 million investment round. This latest major financing initiative was led by institutional investor Queen City Angels to support upcoming Phase 2b clinical evaluations. Alphyn Biologics was established in 2020 by co-founders Neal Koller, Steven Pentelnik, and Gary Pekoe.
Alphyn Biologics has raised $28.3M across 2 funding rounds.
Alphyn Biologics has raised $28.3M in total across 2 funding rounds.
Alphyn Biologics has raised $28.3M in total across 2 funding rounds.
Alphyn Biologics's investors include Tony Shipley, Angel Physicians Fund, Serial Stage Venture Partners, Queen City Angels.
Alphyn Biologics has raised $28.3M across 2 funding rounds. Most recently, it raised $25.0M Series B in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 12, 2025 | $25M Series B | Tony Shipley | Angel Physicians Fund, Serial Stage Venture Partners | Announced |
| Sep 19, 2022 | $3.3M Series A | Queen City Angels | Angel Physicians Fund, Serial Stage Venture Partners | Announced |